This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Other				
Cushing's disease	Nuclear receptor subfamily 2 group C member 2 (NR2C2; TR4)	<p>Patient sample and mouse studies suggest inhibiting TR4 could help treat Cushing's disease. In corticotroph tumors from patients with the disease, TR4 was overexpressed compared with expression in normal corticotroph cells. In mice, injection of the mouse corticotroph tumor cell line pretreated with <i>Nr2c2</i> small hairpin RNA decreased tumor growth and levels of circulating adrenocorticotrophic hormone (ACTH) compared with injection of cells pretreated with scrambled control shRNA. Planned studies include identifying and testing TR4 inhibitors.</p> <p><i>SciBX</i> 6(20); doi:10.1038/scibx.2013.496 Published online May 23, 2013</p>	Patent and licensing status unavailable	<p>Du, L. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online May 7, 2013; doi:10.1073/pnas.1306182110 Contact: Anthony P. Heaney, University of California, Los Angeles, Calif. e-mail: aheaney@mednet.ucla.edu Contact: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, Calif. e-mail: evans@salk.edu</p>